Michael Saylor, Executive Chairman of Strategy, predicts Bitcoin is entering a bull market driven by expanded bank custody, lending services, and securities tokenization over the next 12–24 months. Strategy repurchased about $1.5 billion of its STRC shares to stabilize prices and holds enough cash to cover 3.5 years of dividends. Saylor also discussed the potential for Bitcoin-backed, dollar-pegged stablecoins offering 6%–8% yields, though no issuance plans are currently announced. The viability of such stablecoins depends on collateral, liquidity, regulation, and peg stability, with the broader vision of creating a financial system built around digital capital and faster, always-on markets.
Michael Saylor's Bitcoin outlook provides context for cryptocurrency trends. For readers following crypto markets, here is Pluang's snapshot as of Oct 19, 2026 15:02 WIB: 41 of 50 major cryptocurrencies rose today. EOS gained 8.13% to Rp12.649 with a typical hold time of 87 days. CRV rose 5.16% to Rp6.405, with 57% buy orders and a 62-day hold time. UNI increased 2.94% to Rp133.479, though 86% of orders were sell, with a 65-day hold time.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
